Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?

References

• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature 1971;231:232–5
   Web of Science ®Google Scholar
• Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000;22:500–48
   Google Scholar
• Cooper SA, Needle SE, Kruger GO. Comparative analgesic potency of aspirin and ibuprofen. J Oral Maxillofac Surg 1977;35:898–903
   Google Scholar
• Cooper SA, Engel J, Ladov M, et al. Analgesic efficacy of an ibuprofen–codeine combination. Pharmacotherapy 1982;2: 162–7
   PubMed Web of Science ®Google Scholar
• Cooper SA, Gelb SB, Cavalere MB, et al. An analgesic relative potency assay comparing ketoprofen and aspirin in postoperative dental pain. Adv Ther 1984;1:410–8
   Google Scholar
• Sunshine A, Olson NZ. Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. J Clin Pharmacol. 1988;28(Suppl 12):S47–S54
   Google Scholar
• Forbes JA, Keller CK, Smith JW, et al. Analgesic effect of naproxen sodium, codeine, a naproxen–codeine combination and aspirin on the postoperative pain of oral surgery. Pharmacotherapy 1986;6:211–8
   PubMed Web of Science ®Google Scholar
• Forbes JA, Butterworth GA, Burchfield WH, Beaver WT. Evaluation of ketorolac, aspirin, and an acetaminophen–codeine combination in postoperative oral surgery pain. Pharmacotherapy 1990;10(Suppl):77S–93S
   Google Scholar
• Ferriera SH, Vane JR. New aspects of the mode of action of nonsteroid anti-inflammatory drugs. Annu Rev Pharmacol 1974;14:57–72
   Google Scholar
• Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs – differences and similarities. New Engl J Med 1991;324:1716–25
   PubMed Web of Science ®Google Scholar
• Langman MJS, Weil J, Wainright P, et al. Risk of bleeding peptic ulcer associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994;343:1075–8
   PubMed Web of Science ®Google Scholar
• Penderson AK, Fitzgerald GA. Dose-related kinetics of aspirin, presystemic acetylation of platelet cyclooxygenase. New Engl J Med 1984;311:1206–11
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 2002;99:13371–3
   PubMed Web of Science ®Google Scholar
• Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol. Lancet 2003;361: 981–2
   Google Scholar
• Hla T, Neilson K. Human cyclooxygenase-2 DNA. Proc Natl Acad Sci USA 1992;89:7384–8
   PubMed Web of Science ®Google Scholar
• Fletcher BS, Kujubu DA, Perin DM, Herschman HR. Structure of the mitogen-inducible T1S10 gene and demonstration that the T1S10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338–44
   PubMed Web of Science ®Google Scholar
• O’Banion MK, Sadowski HB, Winn V, Young DA. A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase related protein. J Biol Chem 1991;266: 23261–7
   Google Scholar
• Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–6
   PubMed Web of Science ®Google Scholar
• Crofford IJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997;24(Suppl 149):15–9
   Google Scholar
• Moore PA, Hersh EV. Celecoxib and rofecoxib: the role of COX-2 inhibitors in dental practice. J Am Dent Assoc 2001;132:451–6
   PubMed Web of Science ®Google Scholar
• Bombadier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Schitnizer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004;364:665–74
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study – a randomized controlled trial. J Am Med Assoc 2000;284:1247–55
   Google Scholar
• Food and drug administration joint meeting with the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee [online]. Available from http://www.fda.gov/ohrms/dockets/ac/05/slides/2005–4090s1.htm [accessed 1 May 2005]
   Google Scholar
• Ehrlich K, Sicking C, Respondek M, Peskar BM. Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defense in rats. J Pharmacol Exp Ther 2004;308:277–83
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706–14
   PubMed Web of Science ®Google Scholar
• Gretzer B, Maricic N, Respondek M, et al. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001;132:1565–73
   PubMed Web of Science ®Google Scholar
• Tanaka A, Araki H, Komoike Y, et al. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol (Paris) 2001;95:21–7
   PubMedGoogle Scholar
• Brater CD, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1–15
   PubMed Web of Science ®Google Scholar
• Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70–83
   PubMed Web of Science ®Google Scholar
• Morrison BW, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxygenase inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943–53
   PubMed Web of Science ®Google Scholar
• Malmstrom K, Fricke JR, Kotey P, et al. A comparison of rofecoxib versus celecoxib after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clin Ther 2002;24:1549–60
   PubMed Web of Science ®Google Scholar
• Daniels SE, Grossman EH, Kuss ME, et al. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001,23:1018–31
   PubMed Web of Science ®Google Scholar
• Malmstom K, Kotey P, Coughlin H, Desjardins PJ. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain 2004;20:147–55
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Fricke Jr JR, Gitton X, et al. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose–response studies. Curr Med Res Opin 2005;21:151–61
   PubMed Web of Science ®Google Scholar
• Chang DJ, Fricke JR, Bird SR, et al. Rofecoxib versus codeine/ acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled trial. Clin Ther 2001;23:1446–55
   PubMed Web of Science ®Google Scholar
• Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin 2004;20:939–49
   PubMed Web of Science ®Google Scholar
• Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002;133:611–21
   PubMed Web of Science ®Google Scholar
• Malmstrom K, Ang J, Fricke JR, et al. The analgesic effect of etoricoxib relative to that of two opioid-acetaminophen containing analgesics: a randomized, double-blind, placebo and active comparator controlled single-dose study in acute dental impaction pain. Curr Med Res Opin 2005;21:141–9
   PubMed Web of Science ®Google Scholar
• Cooper SA. Five studies on ibuprofen for postsurgical dental pain. Am J Med 1984;77:70–7
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126\(Suppl 3):234S–64S
   Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. New Engl J Med 2005;352:1092–102
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 352;2005:1071–80
   PubMed Web of Science ®Google Scholar
• Merck announces voluntary worldwide withdrawal of VIOXX® [online]. Available from htpp://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp [accessed 1 October 2004]
   Google Scholar
• Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481–92
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New Engl J Med 352;2005:1081–91
   PubMed Web of Science ®Google Scholar
• FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) [online]. Available from http:// www.fda.gov/cder/drug/advisory/COX2.htm [accessed 7 May 2005]
   Google Scholar
• Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized double-blind, controlled study. Neurology 2004;62:66–71
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib:cumulative meta-analysis. Lancet 2004;364:2021–9
   PubMed Web of Science ®Google Scholar
• Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127: 395–402
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001;286: 954–9
   Google Scholar
• Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts J, van de Laar FJ. Platelet function is inhibited by non-selective nonsteroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002;41:458–61
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468–71
   PubMed Web of Science ®Google Scholar
• Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280–8
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Voinovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563–8
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival D, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558–66
   PubMed Web of Science ®Google Scholar
• Esser R, Berry C, Du Z, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005;144:538–50
   PubMed Web of Science ®Google Scholar
• Wong D, Wang M, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005;5:204–10
   PubMed Web of Science ®Google Scholar
• Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharmaceut Sci 2004;7:332–6
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA. Coxibs and cardiovascular disease. New Engl J Med 2004;351:1709–11
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157–64
   PubMed Web of Science ®Google Scholar
• Farkoush ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004;364:675–84
   PubMed Web of Science ®Google Scholar
• Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715–22
   PubMed Web of Science ®Google Scholar
• Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235–43
   PubMed Web of Science ®Google Scholar
• Graham GG, Scott KF. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology 2003;11:401–13
   PubMedGoogle Scholar
• Botting RH. Mechanisms of action of acetaminophen: is there a cyclooxygenase-3. Clin Infect Dis 2000;31:S202–10
   Web of Science ®Google Scholar
• Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;246:410–1
   Google Scholar
• Willoughby DA, Moore AR, Collville-Nash PR. COX-1, COX-2, COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000;355: 646–8
   Google Scholar
• Chandrasekharan NV, Dai H, Ruos LT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926–31
   PubMed Web of Science ®Google Scholar
• Shaftel SS, Olschowka JA, Hurley SD, et al. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Mol Brain Res 2003;119:213–5
   PubMedGoogle Scholar
• Kis B. Snipes A. Bari F. Busija DW. Regional distribution of cyclooxygenase-3 mRNA in the rat central nervous system. Mol Brain Res 2004;126: 78–80
   Google Scholar
• Dinchuk JE, Liu RQ, Trzaskos JM. COX-3: in the wrong frame in mind. Immunol Lett 2003;86: 121
   Google Scholar
• Kis B, Snipes JA, Isse T, et al. Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 2003;23:1287–92
   PubMed Web of Science ®Google Scholar
• Cui JG, Kuroda H, Chandrasekharan NV, et al. Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells. Neurochem Res 2004;29:1731–7
   PubMed Web of Science ®Google Scholar
• Davies NM, Good RL, Roupe KA, Yanez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? – not as easy as 1, 2, 3. J Pharm Pharmaceut Sci 2004;7:217–26
   PubMed Web of Science ®Google Scholar
• Dou W, Jiao Y, Goorha S, et al. Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG). Prostaglandins Other Lipid Mediat 2004; 74:29–43
   PubMed Web of Science ®Google Scholar
• Ayoub SS, Botting RM, Goorha S, et al. Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein. Proc Natl Acad Sci USA 2004;101:11165–9
   PubMed Web of Science ®Google Scholar
• Kis B, Snipes JA, Simandle SA, Busija DW. Acetaminophen-sensitive prostaglandin production in rat cerebral endothelial cells. Am J Physiol Regul Integr Comp Physiol 2005;288:R897–902
   Google Scholar
• Li S, Wang Y, Matsumura K, et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-l-) but not in cyclooxygenase-1(-l-) mice. Brain Res 1999;825:86–94
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Robertson PM, et al. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci USA 1999;96:3275–80
   PubMed Web of Science ®Google Scholar
• Schwab JM, Beiter T, Linder JU, et al. COX-3 – a virtual pain target in humans? FASEB J 2003;17:2174–5
   PubMed Web of Science ®Google Scholar
• Snipes JA, Kis B, Shelness GS, et al. Cloning and characterization of cyclooxygenase-1b (putative COX-3) in rat. J Pharmacol Exp Ther 2005;313:668–76
   PubMed Web of Science ®Google Scholar
• Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biology 2004;5:241
   PubMed Web of Science ®Google Scholar
• Qin N, Zhang S, Reitz T, et al. Human COX-3? Cloning and characterization of a splicing variant of COX-1. Program No. 287.13. Abstract viewer/itinerary planner. Washington (DC): Society for Neuroscience, 2004. Available from: http://sfn.scholarone.com [accessed 3 June 2005]
   Google Scholar
• Warner TD, Vojnovic I, Giuliano F, et al. Cyclooxygenases 1, 2, 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2 selective inhibitors in rat tissues. J Pharmacol Exp Ther 2004;310:642–7
   PubMed Web of Science ®Google Scholar
• Simmons DL. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003;110:265–8
   PubMed Web of Science ®Google Scholar
• Botting R. COX-1 and COX-3 inhibitors. Thromb Res 2003;110:269–72
   PubMed Web of Science ®Google Scholar
• Kis B, Snipes JA, Busija DW. Acetaminophen and the COX-3 puzzle: sorting out facts, fictions and uncertainties. J Pharmacol Exp Ther 2005;313 [doi:10.1124/jpet.105.085431]
   Google Scholar
• Berenbaum F. COX-3: fact or fancy? Joint Bone Spine 2004;71: 451–3
   Google Scholar